Video: Knock on Wood| Webinar: ACR/CHEST ILD Guidelines in Practice
fa-facebookfa-linkedinfa-youtube-playfa-rss

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

Search results for: psoriasis

Psoriasis, Psoriatic Arthritis Linked with Arrhythmia

Laura Newman  |  

NEW YORK (Reuters Health)—Psoriasis is linked to a higher risk for arrhythmia, independent of classic cardiovascular (CV) risk factors, according to a study from Taiwan. “In my practice, arrhythmia as comorbidity is discussed during patient consultation along with other comorbidities,” said senior author Dr. Tsen-Fang Tsai of the Department of Dermatology at National Taiwan University…

Evidence Lacking for Tests for Psoriasis Patients Using Biologic Agents

Will Boggs, MD  |  

NEW YORK (Reuters Health)—Various organizations recommend dozens of screening and monitoring tests for patients with psoriasis or psoriatic arthritis who are using systemic biologic agents, despite sparse evidence to support any of them. “At a population level, these medications have proven to be very safe and the evidence does not support such extensive and frequent…

Adverse Event Risk Data Drive Evaluation of Psoriasis Treatments

Michele B. Kaufman, PharmD, CGP, RPh  |  

PSOLAR, the Psoriasis Longitudinal Assessment and Registry, is a multicenter, longitudinal, intercontinental, disease-based registry used to identify adverse events from commonly used psoriasis drugs.1 An evaluation of the risk of serious infection from systemic psoriasis treatments was recently published using data from PSOLAR. Ninety-three institutional review boards or ethics committees reported into the registry from…

Many Psoriasis Patients Have Undiagnosed Arthritis

Kathryn Doyle  |  

(Reuters Health)—Up to 15% of people with psoriasis have undiagnosed arthritis that’s related to the skin condition, according to a new review. “The important takeaway,” said Dr. Abby Van Voorhees, director of the Psoriasis and Phototherapy Treatment Center at the Hospital of the University of Pennsylvania in Philadelphia, “would be that further education is needed…

Tofacitinib Effective for Treating Moderate-to-Severe Chronic Plaque Psoriasis

Reuters Staff  |  

NEW YORK (Reuters Health)—Tofacitinib is better than placebo (and noninferior to etanercept) for treating patients with moderate-to-severe chronic plaque psoriasis, according to Pfizer’s OPT Compare trial. In an earlier 12-week, phase 2b, dose-ranging trial, the oral JAK inhibitor tofacitinib proved to be more effective than placebo for treating patients with moderate-to-severe plaque psoriasis. Based on…

Biologic Drugs for Psoriasis Are Rarely Stopped for AEs

Joan Raymond  |  

NEW YORK (Reuters Health)—Real-world psoriasis patients receiving biologic therapies rarely stop taking the drugs because of adverse effects, researchers say. Although data from long-term registries have shown similar results, “the demographics of patients in registries are somewhat different than those of patients in real-world practices,” Dr. Jensen Yeung told Reuters Health by email. “I have…

AstraZeneca Hit after Psoriasis Drug Linked to Suicide Fears

Ben Hirschler  |  

LONDON (Reuters)—AstraZeneca’s hopes of topping $45 billion in revenue by 2023 have been dealt a blow by a problem with an experimental psoriasis drug that the drugmaker had viewed as a potential billion-dollar plus seller. Amgen, its partner on the project, announced late on Friday it was ending a collaboration to develop brodalumab after suicidal…